Subsequent Events [Text Block] |
|
a) |
On December 1, 2017, the company received $6,733
from the exercise of a compensation warrant previously granted. The compensation warrant was exercised at $0.42
and a total of
16,031
common shares were issued. The Company also issued
8,016
warrants with an exercise price of $0.60
and an expiration date of April 3, 2019, related to the compensation warrant. Lexaria also issued
14,634
restricted common shares at an issuance price of $0.82
per shares to settle $12,000
of debt to a director of the Company.
|
|
|
|
|
b) |
On December 1, 2017, Lexaria granted
200,000
stock options with an exercise price of $0.83
and an expiration date of December 1, 2022 to an officer of the Company, pursuant to an existing management contract. Lexaria awarded
250,000
stock warrants with an exercise price of $0.83
and an expiration date of December 1, 2019 to a manager of the Company, pursuant to a management contract.
|
|
|
|
|
c) |
On December 1, 2017, Lexaria awarded a total of
209,056
restricted common shares at an issuance price of $0.82
as required by intellectual property performance thresholds within an existing management consulting contract with the Company divided between three officers and three managers.
|
|
|
|
|
d) |
On December 22, 2017, the Company announced it received $95,857.20
from the exercise of stock warrants and a compensation option certificate previously granted. The compensation option certificate was exercised at $0.42
and a total of
7,200
common shares were issued. This exercise is by a third party who is neither an officer nor a director of the Company. The Company also received for exercise a total of
230,062
warrants previously granted; being
9,000
at $0.14
;
125,400
at $0.273
; and
95,662
at $0.60.
|
|
|
|
|
e) |
On January 10, 2017, the Company announced it received $216,851
from the exercise of warrants and stock options previously granted.
33,375
stock options were exercised at $0.2273
and
50,000
were exercised at $0.295
and
324,191
warrants at $0.60.
|
|